Psoriasis (PSOR) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051130

This document outlines details of PBS-subsidised biological medicines for patients with psoriasis (PSOR).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Psoriasis (PSOR) adult quick reference

Table 1

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB112 form	Written S85: adalimumab bimekizumab etanercept guselkumab infliximab s.c. ixekizumab risankizumab secukinumab tildrakizumab ustekinumab S100: infliximab i.v.	Yes	OPA Database	Must be treated by a: dermatologist	No
First continuing PB113 form	Written S85: adalimumab bimekizumab etanercept guselkumab infliximab s.c. ixekizumab risankizumab secukinumab tildrakizumab ustekinumab S100: infliximab i.v.	No	OPA Database	Must be treated by a: dermatologist	No
Subsequent continuing PB113 form	Written S85: adalimumab bimekizumab etanercept guselkumab infliximab s.c. ixekizumab risankizumab secukinumab tildrakizumab ustekinumab S100: infliximab i.v.	No	OPA Database	Must be treated by a: dermatologist	No
Subsequent continuing - biosimilar brand	Streamlined S85: etanercept adalimumab S100: infliximab i.v. (Telephone for increased quantities of infliximab i.v. for patients>100kg)	No	N/A	Must be treated by a: dermatologist	N/A
Change or recommencement PB263 form	Written S85: adalimumab bimekizumab etanercept guselkumab infliximab s.c. ixekizumab risankizumab secukinumab tildrakizumab ustekinumab S100: infliximab i.v.	Yes	OPA Database	Must be treated by a: dermatologist	No
Balance of supply (top -up)	Telephone Electronic S85: adalimumab bimekizumab etanercept guselkumab infliximab s.c. ixekizumab risankizumab secukinumab tildrakizumab ustekinumab S100: infliximab i.v.	No	OPA	Must be treated by a: dermatologist	Yes
Demonstration of response PB263 form	Written S85: adalimumab bimekizumab etanercept guselkumab infliximab s.c. ixekizumab risankizumab secukinumab tildrakizumab ustekinumab S100: infliximab i.v.	No	Database	Must be treated by a: dermatologist	No
Medical break	Written S85: adalimumab bimekizumab etanercept guselkumab infliximab s.c. ixekizumab risankizumab secukinumab tildrakizumab ustekinumab S100: infliximab i.v.	Yes	Database	Must be treated by a: dermatologist	No

Psoriasis (PSOR) paediatric quick reference

Table 2: etanercept

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial	Telephone Electronic S85: etanercept	No	OPA	Must be treated by a: dermatologist	Yes
Re-treatment	Telephone Electronic S85: etanercept	No	OPA	Must be treated by a: dermatologist	Yes
Completion of course	Streamlined S85: etanercept	No	N/A	Must be treated by a: dermatologist	N/A
Change or recommencement	Telephone Electronic S85: etanercept	No	OPA	Must be treated by a: dermatologist	Yes
Balance of supply (top-up)	Telephone Electronic S85: etanercept	No	OPA	Must be treated by a: dermatologist	Yes

Table 3: ustekinumab

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB320 form	Written S85: ustekinumab	Yes	OPA Database	Must be treated by a: dermatologist	No
Change or recommencement PB320 form	Written S85: ustekinumab	Yes	OPA Database	Must be treated by a: dermatologist	No
Continuing PB319 form	Written S85: ustekinumab	No	OPA Database	Must be treated by a: dermatologist	No
Balance of supply	Telephone Electronic S85: ustekinumab	No	OPA	Must be treated by a: dermatologist	Yes
Demonstration of response PB320 form	Written S85: ustekinumab	No	Database	Must be treated by a: dermatologist	No
Medical break	Written S85: ustekinumab	Yes	Database	Must be treated by a: dermatologist	No

Applications completed on the database

Table 3

Application type

Action

Initial

Create a patient record on the database if needed
Create a new pended entry in the database
Send to a Pharmaceutical Advisor (PA) for assessment
Once PA has assessed application, complete the entry in the database

First continuing

If approved:

Create and complete an entry in the database
Enter the next assessment date (NAD)

Subsequent continuing

No line in the database needed
If approved, enter the next NAD

Change

Recommencement

Create a new pended entry in the database
Send to a PA for assessment
Once PA has assessed application, complete the entry in the database

Balance of supply

No database entry needed.

Demonstration of response

Create and complete a new entry in the database
Update the drug history

Medical break

Create a new pended entry in the database
Send to a PA to action

Current treatment for subsequent continuing applications

Table 4

Step	Action
1	Is the previous next assessment date within 3 months of date of processing? Yes, approve No, go to Step 2
2	Is the application a subsequent continuing for a drug with a biosimilar brand listing? Yes, approve No, go to Step 3
3	Has the prescriber completed current treatment or supplied dates of most recent treatment course on the application form? Yes, approve No, go to Step 4
4	Check dispensing history. Is there a dispensing in the last 3 months? Yes, approve No, go to Step 5
5	Is there a letter or note from the prescriber about a break in treatment? Yes, refer to a Pharmaceutical Advisor (PA) No, reject

Operational Information

Psoriasis (PSOR) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051130

On this page:

Psoriasis (PSOR) adult quick reference

Psoriasis (PSOR) paediatric quick reference

Applications completed on the database

Current treatment for subsequent continuing applications